{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T16:20:07Z","timestamp":1781713207235,"version":"3.54.5"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T00:00:00Z","timestamp":1725667200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T00:00:00Z","timestamp":1725667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R37CA282430"],"award-info":[{"award-number":["R37CA282430"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA016056"],"award-info":[{"award-number":["P30CA016056"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"DOI":"10.13039\/100013700","name":"National Comprehensive Cancer Network","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100013700","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2024,11,2]]},"DOI":"10.1038\/s41416-024-02845-x","type":"journal-article","created":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T06:02:21Z","timestamp":1725688941000},"page":"1290-1297","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["TAS-102, Irinotecan, and bevacizumab in pre-treated metastatic colorectal cancer (TABAsCO), a phase II clinical trial"],"prefix":"10.1038","volume":"131","author":[{"given":"Patrick M.","family":"Boland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarbajit","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iman","family":"Imanirad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6469-4759","authenticated-orcid":false,"given":"Namrata","family":"Vijayvergia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth D.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Medhavi","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renuka V.","family":"Iyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Bakin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0998-4996","authenticated-orcid":false,"given":"Jianxin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Chatley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8340-7950","authenticated-orcid":false,"given":"Beth","family":"Cahill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Vadehra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristopher","family":"Attwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard S.","family":"Hochster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3837-5644","authenticated-orcid":false,"given":"Christos","family":"Fountzilas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,7]]},"reference":[{"key":"2845_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71:7\u201333.","journal-title":"CA Cancer J Clin"},{"key":"2845_CR2","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3322\/caac.21772","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2023. CA Cancer J Clin. 2023;73:233\u201354.","journal-title":"CA Cancer J Clin"},{"key":"2845_CR3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(12)70477-1","volume":"14","author":"J Bennouna","year":"2013","unstructured":"Bennouna J, Sastre J, Arnold D, Osterlund P, Greil R, Van Cutsem E, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 2013;14:29\u201337.","journal-title":"Lancet Oncol"},{"key":"2845_CR4","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1200\/JCO.2012.42.8201","volume":"30","author":"E Van Cutsem","year":"2012","unstructured":"Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausova J, Macarulla T, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012;30:3499\u2013506.","journal-title":"J Clin Oncol"},{"key":"2845_CR5","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S1470-2045(15)70127-0","volume":"16","author":"J Tabernero","year":"2015","unstructured":"Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol. 2015;16:499\u2013508.","journal-title":"Lancet Oncol"},{"key":"2845_CR6","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1634\/theoncologist.2015-0199","volume":"21","author":"KA Bikov","year":"2016","unstructured":"Bikov KA, Mullins CD, Hung A, Seal B, Onukwugha E, Hanna N. Patterns of biologics use across treatment lines in elderly (age >65) medicare patients with metastatic colon cancer. oncologist. 2016;21:676\u201383.","journal-title":"oncologist"},{"key":"2845_CR7","doi-asserted-by":"publisher","first-page":"djt371","DOI":"10.1093\/jnci\/djt371","volume":"106","author":"TA Abrams","year":"2014","unstructured":"Abrams TA, Meyer G, Schrag D, Meyerhardt JA, Moloney J, Fuchs CS. Chemotherapy usage patterns in a US-wide cohort of patients with metastatic colorectal cancer. J Natl Cancer Inst. 2014;106:djt371.","journal-title":"J Natl Cancer Inst"},{"key":"2845_CR8","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.3892\/or.2014.3487","volume":"32","author":"N Tanaka","year":"2014","unstructured":"Tanaka N, Sakamoto K, Okabe H, Fujioka A, Yamamura K, Nakagawa F, et al. Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models. Oncol Rep. 2014;32:2319\u201326.","journal-title":"Oncol Rep"},{"key":"2845_CR9","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/S0006-2952(00)00253-7","volume":"59","author":"M Fukushima","year":"2000","unstructured":"Fukushima M, Suzuki N, Emura T, Yano S, Kazuno H, Tada Y, et al. Structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2\u2019-deoxyribonucleosides. Biochem Pharm. 2000;59:1227\u201336.","journal-title":"Biochem Pharm"},{"key":"2845_CR10","first-page":"545","volume":"13","author":"T Emura","year":"2004","unstructured":"Emura T, Murakami Y, Nakagawa F, Fukushima M, Kitazato K. A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells. Int J Mol Med. 2004;13:545\u20139.","journal-title":"Int J Mol Med"},{"key":"2845_CR11","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1158\/1535-7163.MCT-14-0236","volume":"14","author":"K Matsuoka","year":"2015","unstructured":"Matsuoka K, Iimori M, Niimi S, Tsukihara H, Watanabe S, Kiyonari S, et al. Trifluridine induces p53-dependent sustained G2 phase arrest with its massive misincorporation into DNA and few DNA strand breaks. Mol Cancer Ther. 2015;14:1004\u201313.","journal-title":"Mol Cancer Ther"},{"key":"2845_CR12","doi-asserted-by":"crossref","unstructured":"Alruwaili MM, Zonneville J, Naranjo MN, Serio H, Melendy T, Straubinger RM, et al. A synergistic two-drug therapy specifically targets a DNA repair dysregulation that occurs in p53-deficient colorectal and pancreatic cancers. Cell Rep Med. 2024:101434.","DOI":"10.1016\/j.xcrm.2024.101434"},{"key":"2845_CR13","doi-asserted-by":"publisher","first-page":"393","DOI":"10.3892\/etm.2011.244","volume":"2","author":"N Suzuki","year":"2011","unstructured":"Suzuki N, Nakagawa F, Nukatsuka M, Fukushima M. Trifluorothymidine exhibits potent antitumor activity via the induction of DNA double-strand breaks. Exp Ther Med. 2011;2:393\u20137.","journal-title":"Exp Ther Med"},{"key":"2845_CR14","first-page":"571","volume":"25","author":"T Emura","year":"2004","unstructured":"Emura T, Suzuki N, Yamaguchi M, Ohshimo H, Fukushima M. A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA. Int J Oncol. 2004;25:571\u20138.","journal-title":"Int J Oncol"},{"key":"2845_CR15","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","volume":"372","author":"RJ Mayer","year":"2015","unstructured":"Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N. Engl J Med. 2015;372:1909\u201319.","journal-title":"N. Engl J Med"},{"key":"2845_CR16","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1056\/NEJMoa2214963","volume":"388","author":"GW Prager","year":"2023","unstructured":"Prager GW, Taieb J, Fakih M, Ciardiello F, Van Cutsem E, Elez E, et al. Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer. N. Engl J Med. 2023;388:1657\u201367.","journal-title":"N. Engl J Med"},{"key":"2845_CR17","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1016\/j.annonc.2020.05.024","volume":"31","author":"E Van Cutsem","year":"2020","unstructured":"Van Cutsem E, Danielewicz I, Saunders MP, Pfeiffer P, Argiles G, Borg C, et al. Trifluridine\/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 study. Ann Oncol. 2020;31:1160\u20138.","journal-title":"Ann Oncol"},{"key":"2845_CR18","first-page":"1437","volume":"35","author":"M Nukatsuka","year":"2015","unstructured":"Nukatsuka M, Nakagawa F, Saito H, Sakata M, Uchida J, Takechi T. Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, with irinotecan hydrochloride on human colorectal and gastric cancer xenografts. Anticancer Res. 2015;35:1437\u201345.","journal-title":"Anticancer Res"},{"key":"2845_CR19","first-page":"2577","volume":"7","author":"K Matsuoka","year":"2017","unstructured":"Matsuoka K, Takechi T. Combined efficacy and mechanism of trifluridine and SN-38 in a 5-FU-resistant human colorectal cancer cell lines. Am J Cancer Res. 2017;7:2577\u201386.","journal-title":"Am J Cancer Res"},{"key":"2845_CR20","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1158\/1078-0432.CCR-19-2743","volume":"26","author":"AM Varghese","year":"2020","unstructured":"Varghese AM, Cardin DB, Hersch J, Benson AB, Hochster HS, Makris L, et al. Phase I study of trifluridine\/tipiracil plus irinotecan and bevacizumab in advanced gastrointestinal tumors. Clin Cancer Res. 2020;26:1555\u201362.","journal-title":"Clin Cancer Res"},{"key":"2845_CR21","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"2845_CR22","doi-asserted-by":"publisher","first-page":"6314","DOI":"10.1158\/1078-0432.CCR-21-1789","volume":"27","author":"EG Chiorean","year":"2021","unstructured":"Chiorean EG, Guthrie KA, Philip PA, Swisher EM, Jalikis F, Pishvaian MJ, et al. Randomized phase II study of PARP inhibitor ABT-888 (Veliparib) with modified FOLFIRI versus FOLFIRI as second-line treatment of metastatic pancreatic cancer: SWOG S1513. Clin Cancer Res. 2021;27:6314\u201322.","journal-title":"Clin Cancer Res"},{"key":"2845_CR23","doi-asserted-by":"publisher","first-page":"3580","DOI":"10.1200\/JCO.2023.41.16_suppl.3580","volume":"41","author":"OB Alese","year":"2023","unstructured":"Alese OB, Gbolahan OB, Diab M, Botrus G, Coleman K, McCook-Veal A, et al. OniLon: Phase II trial of trifluridine\/tipiracil (TAS-102) and nanoliposomal irinotecan (nal-IRI) in advanced colorectal cancer. J Clin Oncol. 2023;41:3580.","journal-title":"J Clin Oncol"},{"key":"2845_CR24","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/s41591-023-02240-8","volume":"29","author":"J van de Haar","year":"2023","unstructured":"van de Haar J, Ma X, Ooft SN, van der Helm PW, Hoes LR, Mainardi S, et al. Codon-specific KRAS mutations predict survival benefit of trifluridine\/tipiracil in metastatic colorectal cancer. Nat Med. 2023;29:605\u201314.","journal-title":"Nat Med"},{"key":"2845_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100511","volume":"7","author":"T Yoshino","year":"2022","unstructured":"Yoshino T, Van Cutsem E, Li J, Shen L, Kim TW, Sriuranpong V, et al. Effect of KRAS codon 12 or 13 mutations on survival with trifluridine\/tipiracil in pretreated metastatic colorectal cancer: a meta-analysis. ESMO Open. 2022;7:100511.","journal-title":"ESMO Open"},{"key":"2845_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.102945","volume":"9","author":"J Tabernero","year":"2024","unstructured":"Tabernero J, Taieb J, Fakih M, Prager GW, Van Cutsem E, Ciardiello F, et al. Impact of KRAS(G12) mutations on survival with trifluridine\/tipiracil plus bevacizumab in patients with refractory metastatic colorectal cancer: post hoc analysis of the phase III SUNLIGHT trial. ESMO Open. 2024;9:102945.","journal-title":"ESMO Open"},{"key":"2845_CR27","doi-asserted-by":"publisher","first-page":"S98","DOI":"10.1016\/j.annonc.2020.04.109","volume":"31","author":"R Giampieri","year":"2020","unstructured":"Giampieri R, Zizzi A, Bittoni A, Pecci F, Giglio E, Giulia M, et al. P-27 Retrospective observational analysis of p53 mutational status as a prognostic factor in TAS-102 treated metastatic colorectal cancer patients. Ann Oncol. 2020;31:S98.","journal-title":"Ann Oncol"},{"key":"2845_CR28","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1038\/s42003-021-02370-0","volume":"4","author":"J Zonneville","year":"2021","unstructured":"Zonneville J, Wang M, Alruwaili MM, Smith B, Melnick M, Eng KH, et al. Selective therapeutic strategy for p53-deficient cancer by targeting dysregulation in DNA repair. Commun Biol. 2021;4:862.","journal-title":"Commun Biol"},{"key":"2845_CR29","doi-asserted-by":"publisher","first-page":"3531","DOI":"10.1200\/JCO.2023.41.16_suppl.3531","volume":"41","author":"D Walden","year":"2023","unstructured":"Walden D, Deshmukh S, Batalini F, Zheng-Lin B, Wu S, Xiu J, et al. Chemotherapeutic sensitivity in colorectal cancer expressing low RNA of wild type homologous recombination genes. J Clin Oncol. 2023;41:3531.","journal-title":"J Clin Oncol"},{"key":"2845_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-022-00318-z","volume":"6","author":"LF Spurr","year":"2022","unstructured":"Spurr LF, Martinez CA, Katipally RR, Iyer SC, Pugh SA, Bridgewater JA, et al. A proliferative subtype of colorectal liver metastases exhibits hypersensitivity to cytotoxic chemotherapy. NPJ Precis Oncol. 2022;6:72.","journal-title":"NPJ Precis Oncol"},{"key":"2845_CR31","doi-asserted-by":"publisher","first-page":"3146","DOI":"10.1002\/jps.24455","volume":"104","author":"K Takahashi","year":"2015","unstructured":"Takahashi K, Yoshisue K, Chiba M, Nakanishi T, Tamai I. Involvement of concentrative nucleoside transporter 1 in intestinal absorption of trifluridine using human small intestinal epithelial cells. J Pharm Sci. 2015;104:3146\u201353.","journal-title":"J Pharm Sci"},{"key":"2845_CR32","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/bdd.2110","volume":"39","author":"K Takahashi","year":"2018","unstructured":"Takahashi K, Yoshisue K, Chiba M, Nakanishi T, Tamai I. Contribution of equilibrative nucleoside transporter(s) to intestinal basolateral and apical transports of anticancer trifluridine. Biopharm Drug Dispos. 2018;39:38\u201346.","journal-title":"Biopharm Drug Dispos"},{"key":"2845_CR33","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.3892\/ijo.2015.2974","volume":"46","author":"K Sakamoto","year":"2015","unstructured":"Sakamoto K, Yokogawa T, Ueno H, Oguchi K, Kazuno H, Ishida K, et al. Crucial roles of thymidine kinase 1 and deoxyUTPase in incorporating the antineoplastic nucleosides trifluridine and 2\u2019-deoxy-5-fluorouridine into DNA. Int J Oncol. 2015;46:2327\u201334.","journal-title":"Int J Oncol"},{"key":"2845_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-44399-6","volume":"9","author":"Y Kataoka","year":"2019","unstructured":"Kataoka Y, Iimori M, Niimi S, Tsukihara H, Wakasa T, Saeki H, et al. Cytotoxicity of trifluridine correlates with the thymidine kinase 1 expression level. Sci Rep. 2019;9:7964.","journal-title":"Sci Rep"},{"key":"2845_CR35","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1158\/1541-7786.MCR-17-0686","volume":"16","author":"K Edahiro","year":"2018","unstructured":"Edahiro K, Iimori M, Kobunai T, Morikawa-Ichinose T, Miura D, Kataoka Y, et al. Thymidine kinase 1 loss confers trifluridine resistance without affecting 5-fluorouracil metabolism and cytotoxicity. Mol Cancer Res. 2018;16:1483\u201390.","journal-title":"Mol Cancer Res"},{"key":"2845_CR36","doi-asserted-by":"publisher","first-page":"e719","DOI":"10.1016\/j.clcc.2018.07.009","volume":"17","author":"T Yoshino","year":"2018","unstructured":"Yoshino T, Yamazaki K, Shinozaki E, Komatsu Y, Nishina T, Baba H, et al. Relationship between thymidine kinase 1 expression and trifluridine\/tipiracil therapy in refractory metastatic colorectal cancer: a pooled analysis of 2 randomized clinical trials. Clin Colorectal Cancer. 2018;17:e719\u2013e32.","journal-title":"Clin Colorectal Cancer"},{"key":"2845_CR37","unstructured":"Yoshisue K, Takahashi K, Okayama T, Yamashita F, Chiba M, editors. Investigation of transporters that play an important role in urinary secretion of thymidine phosphorylase inhibitor combined with a novel anti-cancer agent of TAS-102. DRUG METABOLISM REVIEWS; 2015: TAYLOR & FRANCIS LTD 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON."},{"key":"2845_CR38","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.ejca.2017.08.033","volume":"86","author":"M Suenaga","year":"2017","unstructured":"Suenaga M, Schirripa M, Cao S, Zhang W, Yang D, Dadduzio V, et al. Potential role of polymorphisms in the transporter genes ENT1 and MATE1\/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer. Eur J Cancer. 2017;86:197\u2013206.","journal-title":"Eur J Cancer"},{"key":"2845_CR39","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1093\/annonc\/mdx035","volume":"28","author":"M Suenaga","year":"2017","unstructured":"Suenaga M, Schirripa M, Cao S, Zhang W, Yang D, Murgioni S, et al. Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer. Ann Oncol. 2017;28:1015\u201322.","journal-title":"Ann Oncol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-024-02845-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-024-02845-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-024-02845-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T15:05:18Z","timestamp":1728918318000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-024-02845-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,7]]},"references-count":39,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,11,2]]}},"alternative-id":["2845"],"URL":"https:\/\/doi.org\/10.1038\/s41416-024-02845-x","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,7]]},"assertion":[{"value":"4 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Christos Fountzilas has research support for this clinical trial from the National Comprehensive Cancer Network Oncology Research Program (paid to the institute). He has research support from the National Comprehensive Cancer Network Foundation, Taiho Oncology, Pfizer Inc, and Merck Sharp & Dohme Corp (paid to the institute) unrelated to this study. Dr. Sarbajit Mukherjee has received research funding from Ipsen Biopharmaceuticals (paid to the institute) unrelated to this study. Dr. Iman Imanirad has received advisory board compensation from Eisai Co, Ltd, unrelated to this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was conducted according to the Declaration of Helsinki principles and approved by the Institutional Review Boards (IRB) from all participating institutions (Roswell Park Comprehensive Cancer Center, Rutgers Cancer Institute of New Jersey, Moffitt Cancer Center, and Fox Chase Comprehensive Cancer Center). All patients provided informed consent prior to study participation. All patients providing tumor samples for whole transcriptome sequencing (de-identified Roswell Park IRB-approved protocols BDR 155422 and BDR 151721) had provided universal informed consent for use of tumor samples in research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}